Grail (GRAL) and Its Competitors Financial Review

Grail (NASDAQ:GRAL) is one of 48 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its competitors? We will compare Grail to similar companies based on the strength of its dividends, valuation, earnings, analyst recommendations, risk, profitability and institutional ownership.

Institutional & Insider Ownership

47.5% of shares of all “Medical laboratories” companies are held by institutional investors. 1.9% of Grail shares are held by company insiders. Comparatively, 15.6% of shares of all “Medical laboratories” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Grail and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Grail	$130.71 million	N/A	-0.72
Grail Competitors	$1.05 billion	-$110.55 million	-5.87

Grail’s competitors have higher revenue, but lower earnings than Grail. Grail is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Grail and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grail	0	3	1	0	2.25
Grail Competitors	371	1443	2420	42	2.50

Grail presently has a consensus target price of $31.50, indicating a potential downside of 28.20%. As a group, “Medical laboratories” companies have a potential upside of 1,308.21%. Given Grail’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Grail has less favorable growth aspects than its competitors.

Profitability

This table compares Grail and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grail	N/A	N/A	N/A
Grail Competitors	-3,479.68%	-975.07%	-26.59%

Summary

Grail competitors beat Grail on 7 of the 11 factors compared.

About Grail

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.